4584 — Kidswell Bio Share Price
0.000.00%
Last trade - 00:00- ¥5bn
- ¥6bn
- ¥3bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.8 | ||
| Price to Tang. Book | 3.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.69% | ||
| Return on Equity | -77.27% | ||
| Operating Margin | -43.79% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 1,021.7 | 1,077.74 | 996.54 | 1,569.23 | 2,776.24 | n/a | n/a | 21.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
Directors
- Masaharu Tani PRE (43)
- Yoshikazu Amano CTO
- Masayuki Kawakami EXO
- Shinya Kurebayashi EXO
- Eisaku Nakamura EXO
- Munechika Sakabe EXO
- Yasuo Sakae EXO
- Masakuni Ueno EXO (64)
- Masatoshi Mitsuki OTH (38)
- Shinichi Uraike OTH (64)
- Ryo Noguchi DRC (37)
- Norikazu Eiki IND (73)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 1st, 2001
- Public Since
- November 30th, 2012
- No. of Shareholders
- 8,837
- No. of Employees
- 41
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 38,939,820
- Address
- 3F, Kanayama Bldg., 1-2-12, Shinkawa, CHUO-KU, 104-0033
- Web
- https://www.kidswellbio.com/
- Phone
- +81 362229547
- Auditors
- Minami Aoyama Audit Corporation
Upcoming Events for 4584
Similar to 4584
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Kidswell Bio share price?
As of Today at 19:12 UTC, shares in Kidswell Bio are trading at ¥141. This share price information is delayed by 15 minutes.
How has the Kidswell Bio share price performed this year?
Shares in Kidswell Bio last closed at ¥141 and the price had moved by -43.82% over the past 365 days. In terms of relative price strength the Kidswell Bio share price has underperformed the Nikkei 225 Index by -57.72% over the past year.
What are the analyst and broker recommendations for Kidswell Bio?
The overall consensus recommendation for Kidswell Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kidswell Bio dividend yield?
Kidswell Bio does not currently pay a dividend.
Does Kidswell Bio pay a dividend?
Kidswell Bio does not currently pay a dividend.
When does Kidswell Bio next pay dividends?
Kidswell Bio does not currently pay a dividend.
How do I buy Kidswell Bio shares?
To buy shares in Kidswell Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kidswell Bio?
As of the previous close price of ¥141, shares in Kidswell Bio had a market capitalisation of ¥5bn.
Where are Kidswell Bio shares listed?
Here are the trading details for Kidswell Bio:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4584
What kind of share is Kidswell Bio?
Based on an overall assessment of its quality, value and momentum Kidswell Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kidswell Bio share price forecast for 2024?
The analyst consensus target price for shares in Kidswell Bio is ¥800. That is 467.38% above the last closing price of ¥141.
Analysts covering Kidswell Bio currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Kidswell Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kidswell Bio. Over the past six months, its share price has underperformed the Nikkei 225 Index by -12.38%.
As of the last closing price of ¥141, shares in Kidswell Bio were trading -10.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kidswell Bio PE Ratio?
The Kidswell Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥141.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kidswell Bio?
Kidswell Bio's management team is headed by:
- Masaharu Tani - PRE
- Yoshikazu Amano - CTO
- Masayuki Kawakami - EXO
- Shinya Kurebayashi - EXO
- Eisaku Nakamura - EXO
- Munechika Sakabe - EXO
- Yasuo Sakae - EXO
- Masakuni Ueno - EXO
- Masatoshi Mitsuki - OTH
- Shinichi Uraike - OTH
- Ryo Noguchi - DRC
- Norikazu Eiki - IND